US EditionAfter FDA exit, Peter Marks pops up at Lilly
Kennedy's anti-vaccine policies have led to $500 million cuts in vaccine research and the loss of experienced public health officials, raising concerns about preventable deaths, experts say.
- On October 7, 2025, Peter Marks joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease after leaving the FDA in March, forced out by HHS Secretary Robert F. Kennedy Jr.
- Kennedy has repeatedly peddled false claims about vaccines, slashing at least $500 million in mRNA research and purging staff at NIH, FDA, and CDC.
- In his resignation, Peter Marks, former CBER director, wrote that `truth and transparency are not desired by the secretary`, and warned the U.S. faces a terrible state of preparedness as trained FDA, CDC, and NIH staff are gone.
- Critics say Peter Marks’ jump to Eli Lilly fuels revolving-door concerns, recalling transitions by former FDA officials such as Scott Gottlieb and Patrizia Cavazzoni.
- Experts warn that amid systematic changes at Health and Human Services , dismantling major infrastructure risks public health, with historical public-health reforms often triggered by mass casualty events.
12 Articles
12 Articles
Former Top FDA Vaccine Regulator, RFK Jr. Critic Lands New Job At Pharma Giant
Peter Marks, the former head of the FDA’s Center for Biologics Evaluation and Research (CBER) and a prominent critic of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., landed a new job at pharma giant Eli Lilly. Marks will join the company as senior vice president of molecule discovery and head of infectious disease. “Peter’s expertise strengthens our abilities across multiple areas, both in our existing portfolio and in our wor…
Former Top FDA Vaccine Regulator, RFK Jr. Critic Lands New Job At Pharma Giant * 100PercentFedUp.com * by Danielle
Peter Marks, the former head of the FDA’s Center for Biologics Evaluation and Research (CBER) and a prominent critic of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., landed a new job at pharma giant Eli Lilly. Marks will join the company as senior vice president of molecule discovery and head of infectious disease. “Peter’s expertise strengthens our abilities across multiple areas, both in our existing portfolio and in our wor…
Former FDA Vaccine Chief Peter Marks Joins Pharmaceutical Company
Dr. Peter Marks, who formerly led the Food and Drug Administration’s oversight of vaccines, has joined the pharmaceutical firm Eli Lilly, the company told The Epoch Times on Oct. 7. “Lilly continually evaluates breakthrough science which could benefit patients. Peter’s expertise strengthens our abilities across multiple areas, both in our existing portfolio and in our work in emerging areas,” a spokesperson for the company told The Epoch Times v…
Coverage Details
Bias Distribution
- 40% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
